Navigation Links
US Patent Allowed for NOD Tech
Date:11/24/2009

SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmaceuticals Inc. announced the US Patent & Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or NOD technology.

NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD technology is a platform technology that can be applied to many macromolecular drugs such as insulin, interferon, growth hormone, exenatide, heparin and more.

Currently, an oral insulin formulation, the first candidate developed with NOD technology, is entering phase I clinical studies in China.

"Patent allowance for NOD technology is a major step forward for NOD", quoted from William Lee, CEO. "With this patent, and in combination with others, NOD is building a solid foundation for its intellectual property and core competence."

    For more information, please contact:

     William Lee, Ph.D., CEO
     Phone: +86-21-6194-0758
     Email: info@nodpharm.com


    Notes for Editors

About NOD Pharmaceuticals

NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

More information can be found at http://www.nodpharm.com .

SOURCE NOD Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information
2. BioLife Solutions Granted Japanese Biopreservation Patent
3. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
4. AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform
5. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
6. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
7. Athera Receives Allowance of Two Key Patents
8. Jeremy M. Stipkala to Lead Symposium Entitled Patent Law Developments at SERMACS 2009
9. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
10. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
11. Martek Announces Settlement of Patent Dispute with Capsugel France
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... DrugDev ... biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. ... most progressive clinical research leaders for best practice case studies, keynote presentations, lively ...
(Date:9/14/2017)... Australia (PRWEB) , ... September 14, 2017 , ... ... first viscoelastic Freedom Lumbar Disc case in Australia. Dr. Steven Yang completed the ... pain as a result of a degenerative lumbar disc at level L5-S1. The ...
(Date:9/14/2017)... ... September 14, 2017 , ... Cambridge Semantics , ... announced that its Anzo Smart Data Lake has been named a KMWorld ... solutions that help organizations succeed in surpassing their knowledge management goals. KMWorld searches ...
(Date:9/12/2017)... , ... September 12, 2017 , ... ... and highly scalable cloud-based platform for ambulatory patient monitoring and clinical trial support, ... Advance Clinical Trials conference in Boston. , Launched in 2005, PhysIQ leverages ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):